Rights-Based Medicine vs Evidence-Based Medicine

Why “there is no evidence” is not a scientific verdict but a discretionary refusal. The COVID demonstration of the fracture line, the funding loop that makes the demand for evidence self-fulfilling, and the two questions rights-based medicine hands back to those who invoke it.

The pivotal fact about a modern refusal to correct a documented physiological deficit is that it is always phrased as a scientific statement. There is no conclusive evidence that this nutrient prevents this disease. The person carrying the deficit hears it as a scientific verdict on their body. It is nothing of the kind. It is a discretionary ceiling installed above their physiology, dressed in the language of the discipline that is supposed to serve them.

Rights-based medicine was named to refuse this move. Its polemical purpose is not to displace evidence-based medicine as a method of comparing interventions between themselves. It is to refuse the extension of that method into a jurisdiction it was never designed to occupy: the jurisdiction of what a person is owed.

What “there is no evidence” actually says

When the sentence there is no conclusive evidence for vitamin D against COVID-19 was pronounced in 2020 and 2021 by public health authorities, mainstream press, and the science-communication class, three moves were being made in one utterance.

First, the question was displaced. It moved from does this person have adequate vitamin D? to does vitamin D prevent this specific disease? The physiological substrate was replaced by a disease endpoint. The person was replaced by a hypothesis.

Second, an evidentiary standard was imported. The standard was the large randomised controlled trial with a specific disease outcome, powered on a specific effect size. That standard has never been met for most established public health advice, and was never applied retrospectively to the recommendations already in force. It was activated selectively for the intervention that had no economic sponsor.

Third, absence of that specific evidence was treated as a positive ground for withholding correction. The correction was not withheld pending investigation. It was withheld because the specific investigation had not been undertaken. Non-evidence became a reason to leave a documented deficiency in place.

The COVID demonstration

The pandemic offered the clearest instance in living memory of the frame at work. Populations known to be at high risk of vitamin D insufficiency (people with darker pigmented skin, people with high body mass, people over seventy, people who spent long months indoors) were also disproportionately affected by severe COVID-19. The correlation was mechanistic before it was epidemiological. Vitamin D is required for the immune response to respiratory infection. The receptors are known. The pathways are known. The deficiencies were known and had been known for decades.

Two responses formed side by side.

At the government level in the United Kingdom, the Department of Health began delivering 400 IU of vitamin D to about 2.5 million clinically extremely vulnerable people and care-home residents for the winter of 2020-2021. The gesture was modest, the dose was calibrated to bone-health baselines rather than to the actual replacement needs of pigmented or obese populations, and the programme was opt-in. It nonetheless recognised in principle that a physiological deficit is a matter for institutional response.

At the community level, organisations closer to affected populations went further. The Caribbean and African Health Network distributed 2000 IU tablets to African-Caribbean communities in the United Kingdom, on the biologically correct premise that darker pigmented skin blocks the ultraviolet-B synthesis on which the RDA calculations rest. The dose was five times the government’s; the target was calibrated to physiology, not to a population-averaged floor.

In one North American jurisdiction, advocates for targeted distribution to darker-pigmented, obese, and elderly residents were met with the sentence there is no conclusive evidence, and were in some cases treated as adjacent to conspiratorial claims about the pandemic. In India, where roughly 490 million people are vitamin D deficient, no national distribution programme was launched. A subcontinent’s deficit was left in place.

Zinc followed the same pattern. Its role in innate antiviral immunity is textbook. Its deficiency is common. Its distribution as a matter of preparedness was refused on the same procedural grounds. Other parameters plausibly implicated in the modulation of viral outcomes (selenium, magnesium, vitamin K, adequate protein) received the same silence.

The lesson was not epidemiological. It was institutional. The system’s default response to a request that it correct a documented physiological deficiency is to require an evidence class that was never applied to its own recommendations and that no funder had ever provided.

The asymmetry that makes “no evidence” self-fulfilling

Well-designed trials of nutrients rarely produce results as clean as trials of patented molecules. The reason is not that nutrients are less effective. The reason is that the trials are not built at the same scale. Nutrient trials are small, underpowered, single-centre, cross-sectional. Trials of new molecules are large, multi-centre, industry-financed, prospective, tightly designed on populations chosen to maximise effect size.

Funding is what makes the difference, and funding follows economic return. A molecule the body already makes cannot be exclusively licensed. A vitamin cannot be repriced. A mineral cannot be branded. The engine that produces gold-standard trial evidence has no reason to point itself at substrates that are already, in principle, available at low cost. It points itself elsewhere.

The demand that nutrients meet a standard of evidence that only industry-financed molecules can produce is therefore not a scientific demand. It is a demand for evidence a funding architecture is structured to withhold. Absence of that evidence is then invoked as ground for withholding correction. This is a closed loop, and it forecloses a class of physiological interventions on procedural grounds, not on grounds of biological plausibility.

The reason to give a person a nutrient

The reason to give a person a nutrient is not that a trial has shown the nutrient prevents a specific disease. The reason is that the person needs the nutrient. The therapeutic effect of correcting the deficit, on any specific disease or on none, is a downstream and desirable byproduct.

Rights-based medicine returns to this axis. What is owed is what the physiology requires. The disease-specific trial is a tool for comparing interventions in the space of contested treatments. It is not a tool for determining what a body is owed. When it is used as such a tool, it is being asked to do something it was not designed to do.

Once several parameters are restored together, the effects include improvements in conditions no single-nutrient, single-endpoint trial can be designed to test. This is not a mystical addition to the argument. It is the ordinary result of restoring a body to something like the state in which its systems are meant to function. The RCT design is a filter that excludes the multi-parameter case by construction. That the filter is called “the gold standard” is a fact about the sociology of the profession, not about the biology of the person on the receiving end.

Who is negligent?

The charge of unscientific practice was, throughout the pandemic, aimed at those who wanted to correct documented deficiencies without waiting for a COVID-specific trial. The reverse charge is more grounded.

To leave a documented deficiency in place because a specific trial has not been done is not scientific conservatism. It is failure to treat what is treatable. When several such deficits are left untouched in the same person, in the same clinic, over years, the failure is not conservatism either. It is negligence at the physiological level, spread across the professional cohort trained not to see it.

Once the frame is inverted, the accusation of anti-science is where the frame’s operator sits, not where the person asking for correction sits.

Two questions

Two questions are owed to any professional, institution, or communicator that responds to a claim of physiological right with there is no evidence.

What is your evidence that you can deny a body what it needs?

How many rights do you infringe when you assemble a cohort of measurably deficient people, randomise them, and give half of them a placebo to test what would relieve them?

These are not rhetorical. They are the questions any doctrine that calls itself evidence-based has to answer before it can be received as a doctrine, and not as a preference for a certain kind of ignorance.

Rights-based medicine is not the opposite of evidence-based medicine. It is the frame in which evidence-based medicine can be a discipline for comparing treatments rather than a discretionary ceiling installed above human physiology. Everything the discipline has been asked to be that lies above that ceiling belongs to a different jurisdiction. That jurisdiction has a name. Its instruments already exist. See The Instruments Already Exist for the doctrinal architecture on which the argument rests.